AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01644136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional lymph node dissection
Description: Undergo pelvic lymph node dissection
Study NCT01644136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microsphere-mediated lymphocele prevention
Description: Undergo microsphere-mediated lymphocele prevention
Study NCT03521648 — intervention group
Intervention type: PROCEDURE
Intervention: PAE
Description: Prostatic artery embolization
Study NCT03521648 — intervention group
Intervention type: PROCEDURE
Intervention: TURP
Description: Transurethral resection of the prostate
Study NCT03521648 — intervention group
Intervention type: PROCEDURE
Intervention: Other
Description: Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
Study NCT04223778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOR/ISL
Description: A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
Study NCT04223778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: A FDC of 100 mg DOR/ 0.75 mg ISL taken in tablet form, orally, once daily
Study NCT04223778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: Baseline background ART regimen will be administered as per approved label. ART medication will not be provided by the Sponsor; participants will provide their own ART medications. Allowed drug classes include nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transferase inhibitors (InSTIs), fusion inhibitors, chemokine receptor 5 (CCR5) antagonists, post-attachment inhibitor, and pharmacokinetic (PK) boosters.
Study NCT01706848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Celotres
Description: Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
Study NCT01706848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Closure by Standard of Care
Description: Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
Study NCT03013244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Body Project: More Than Muscles
Description: Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
Study NCT01362686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
Study NCT01362686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
Study NCT04816799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Startle Adjuvant Rehabilitation Therapy (START)
Description: Exposure to loud acoustic stimulus during training of motor task (in this case speech).
Study NCT03811587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking diet
Description: The fasting mimicking diet is though to activate the metabolism as fasting would do, although the diet does include several meals a day and more calories than conventional fasting diets.
Study NCT00307931 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks.
Study NCT03244124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Etching Application Strategy
Description: In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
Study NCT01362686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
Study NCT01552187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg BID or colchicine 0.5mg (\<70kg) 48 to 72 hours before surgery till 1 months after surgery
Study NCT01552187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 48 to 72 hours before surgery till 1 months after surgery
Study NCT00311558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: SSG x 5 week
Study NCT00311558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium stibogluconate
Description: SSG \& IFN
Study NCT00311558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSG & interferon
Description: 1 arm study with SSG \& interferon
Study NCT02117596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: 1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours).
Study NCT00063583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
Study NCT00063583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
Study NCT01357304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group treatment and PAR
Description: Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
Study NCT03226132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia
Description: Brief Behavioral Therapy for Insomnia
Study NCT03226132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Repeated Contact
Description: Repeated Contact
Study NCT01969799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin fosfomycin inhalation solution
Description: 300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
Study NCT01969799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aerosolized placebo
Description: Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
Study NCT01766882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower sodium intervention
Description: 1. Lower sodium intervention:~1. Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately >180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~2. Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants.
Study NCT01766882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Challenge to Post Dialysis Weight
Description: The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
Study NCT03244124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enamel Etching Application Strategy
Description: In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
Study NCT01479374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-4943A ophthalmic solution
Study NCT01479374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-4943A vehicle
Description: Inactive ingredients used as placebo
Study NCT01479374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.2%
Study NCT00039195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00039195 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00039195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00039195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00039195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT03244124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etch&Rinse Dry Application Strategy
Description: In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
Study NCT03244124 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Etch&Rinse Wet Application Strategy
Description: In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
Study NCT02224573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Study NCT03310645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1817080
Description: 4 different doses over the course of study
Study NCT03823989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promitil
Description: The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
Study NCT01546935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
Study NCT00039195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT03310645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Matching placebo for BAY1817080
Study NCT03310645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo for BAY1817080
Study NCT03823989 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBR
Description: A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
Study NCT01489904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOTULINUM NEUROTOXIN TYPE-A
Description: Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
Study NCT02410772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine
Description: Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
Study NCT03381053 — intervention group
Intervention type: DRUG
Intervention: Imatinib 400mg
Description: The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
Study NCT03643939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Catheter
Description: HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2.
Study NCT03643939 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
Study NCT02755181 — intervention group
Intervention type: BEHAVIORAL
Intervention: Experimental
Description: with functional imaging and behavioural measurements at baseline and 4 weeks
Study NCT02410772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifapentine and moxifloxacin
Description: Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
Study NCT02410772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: standard six-month treatment
Study NCT04143204 — intervention group
Intervention type: OTHER
Intervention: Oral nutritional intake
Description: The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
Study NCT00039195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00039195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00039195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00039195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00039195 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02455869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SRP and Placebo gel
Description: After SRP, placebo gel was delivered subgingivally into the pocket
Study NCT02455869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP and Atorvastatin
Description: After SRP, Atorvastatin gel was delivered subgingivally into the pocket
Study NCT02455869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP and Alendronate
Description: After SRP, Alendronate gel was delivered subgingivally into the pocket
Study NCT04585308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transShield Embolic Protection System
Description: Used for embolic protection during TAVR.
Study NCT04020640 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: Measure human intake using stable isotope technique
Study NCT01731613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: human milk fortifier
Description: Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
Study NCT01731613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: human milk fortifier
Description: Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
Study NCT02243358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox6
Study NCT02243358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02243358 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT02243358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy with retroperitoneal lymphadenectomy
Study NCT04490252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting mimetic diet
Description: Fasting mimetic diet for 5 days, another cycle after 25 days
Study NCT02948114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Cow milk-based infant formula
Study NCT00926614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone (Actos)
Description: pioglitazone 30 mg qd for 30 days, then increase to 45 mg
Study NCT00926614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin (Lipitor)
Description: atorvastatin 40 mg for 30 days then increase to 80 mg daily
Study NCT05456048 — intervention group
Intervention type: DRUG
Intervention: VAH regimen
Description: VEN was prescribed as 100mg day 1, 200mg day 2, 400mg day 3-14; AZA was used at the dose of 75 mg/m2, day 1-7; HHT was given at a dose of 1mg/m2, day 1-7. The dose of VEN was reduced to 100mg/d if co-administered with posaconazole or voriconazole.
Study NCT02948114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 1: Cow milk-based infant formula
Description: Experimental 1: Cow milk-based infant formula with prebiotics
Study NCT02948114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 2: Cow milk-based infant formula
Description: Experimental 2: Cow milk-based infant formula with probiotics
Study NCT02948114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 3: Cow milk-based infant formula
Description: Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
Study NCT04591067 — intervention group
Intervention type: OTHER
Intervention: Testing of physical capacity
Description: This cross-sectional study will involve evaluation of physical capacity by assessment of:~1. Gait function~2. Muscle activity during walking~3. Endurance during walking~4. Hip muscle strength~5. Hip range of motion~6. Hip and muscle-tendon-related groin pain~7. Hip and groin related patient-reported outcome measures (PROMs)
Study NCT01229644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib (CP-868,596)
Description: Highly potent inhibitor of both PDGFR receptors alpha and beta